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Objectives. The effects of both temporary and permanent dual-
chamber pacing (DCP) were evaluated in symptomatic pediatric
patients with hypertrophic obstructive cardiomyopathy (HOCM)
unresponsive to medications.
Background. Permanent DCP pacing can reduce left ventricu-
lar outflow tract (LVOT) gradient and relieve symptoms in adult
patients with HOCM.
Methods. Ten patients (mean [6SD] age 11.1 6 6 years, range
1 to 17.5) with HOCM and a Doppler LVOT gradient >240 mm Hg
were studied. The seven patients showing hemodynamic improve-
ment during temporary pacing at cardiac catheterization under-
went surgical implantation of a permanent DCP system. The
effects of permanent pacing were evaluated using a questionnaire,
Doppler evaluation, treadmill testing and repeat cardiac cathe-
terization.
Results. At initial cardiac catheterization, three patients failed
to respond to temporary pacing (inadequate pace capture in two;
congenital mitral valve abnormality in one). The remaining seven
patients (70%, 95% confidence interval 38.0% to 91.7%; mean age
13 6 years, range 4 to 17.5) showed a significant reduction (p <
0.05) in LVOT gradient, left ventricular systolic pressure and
pulmonary capillary wedge pressure. After pacemaker implanta-
tion, these seven patients reported a significant reduction in
dyspnea on exertion and exercise intolerance. Serial Doppler
evaluation showed a significant reduction in LVOT gradient.
Follow-up catheterization at 23 6 4 months in six patients (one
patient declined restudy) showed a persistent decrease in LVOT
gradient (53 6 13 vs. 16 6 11 mm Hg), left ventricular systolic
pressure (1496 16 vs. 1086 14 mm Hg) and pulmonary capillary
wedge pressure (186 2 vs. 126 4 mmHg) versus preimplantation
values.
Conclusions. Permanent DCP is an effective therapy for se-
lected pediatric patients with HOCM. Rapid atrial rates and
intrinsic atrioventricular conduction, as well as congenital mitral
valve abnormalities, may preclude effective pacing in certain
patients.
(J Am Coll Cardiol 1997;29:734–40)
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Children with hypertrophic obstructive cardiomyopathy
(HOCM) present special challenges in management. Unlike
adult patients, they have progressive left ventricular hypertro-
phy, are more likely to die suddenly and frequently present
with overt congestive heart failure (1–7). Current treatment of
HOCM includes pharmacologic management or surgical re-
section of obstructing left ventricular outflow tract (LVOT)
muscle reserved for nonresponsive patients. These treatment
options may have significant side effects and are not believed to
alter the natural history of this disorder (3,5,8–15). Less than
optimal clinical outcomes using current treatment regimens
have led investigators to search for alternate, more effective
approaches.
In 1975, Hassenstein et al. (16) performed right ventricular
pacing in four adults with HOCM, finding symptomatic im-
provement and a 56% reduction in LVOT gradient. Over the
ensuing years, other investigators (17–20) have reported de-
creased symptoms and LVOT gradients, as well as improved
diastolic function (20,21).
Based on these findings, we speculated that dual-chamber
pacing (DCP) may have similar benefits for pediatric patients
with HOCM. The specific aim of the present study was to test
the following hypotheses: 1) temporary transvenous DCP
during cardiac catheterization acutely decreases LVOT gradi-
ent; and 2) long-term DCP promotes subjective and objective
improvement in pediatric patients with HOCM.
Methods
Study patients. The study group included 10 pediatric
patients (1 to 17.5 years old) with an echocardiographic
diagnosis of HOCM and a rest Doppler maximal instantaneous
gradient$40 mm Hg across the LVOT gradient. Patients were
chosen without regard to gender, race or ethnic background.
The study was approved by the Emory University School of
Medicine Human Investigations Committee, and all proce-
dures were performed in accordance with institutional guide-
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lines. Written informed consent was obtained from all
individuals/guardians participating in the study.
Preevaluation and follow-up schedule. Before catheteriza-
tion, each patient completed a questionnaire regarding symp-
toms and underwent outpatient 24-h Holter monitor, LVOT
Doppler evaluation and exercise treadmill testing (all patients
$8 years age), followed by cardiac catheterization with tem-
porary DCP. After placement of a permanent pacemaker,
patients were reevaluated in the pacemaker clinic. During
these visits, complete pacemaker analysis and blinded contin-
uous wave Doppler to document LVOT gradient at different
pacing rates, modes and atrioventricular (AV) intervals were
performed. Twenty-four hour Holter monitoring was repeated
at 6, 12 and 18 months, and exercise treadmill testing was
repeated at 6 months. Follow-up hemodynamic catheterization
to evaluate the long-term effects of permanent DCP was
planned at least 18 months after implantation of the pacing
system.
Questionnaire. Each patient and family was questioned
about history of chest pain, shortness of breath, dyspnea on
exertion, exercise intolerance, palpitations, dizziness, presyn-
cope and syncope (rating the response as 0 [never] to 5
[always]), as well as the use of any medications. At postimplan-
tation pacemaker clinic visits, patients were specifically asked
to grade their present condition as “worse,” “unchanged,”
“improved” or “asymptomatic.” A follow-up questionnaire was
administered at the time of repeat cardiac catheterization.
Echocardiography and Doppler. Complete two-dimensional
echocardiography with Doppler was initially performed to
analyze structural abnormalities and to document the rest
LVOT gradient using a Hewlett-Packard Sonos or 1000 or
Sonos 1500 real-time, phased-array ultrasound scanner. Two-
dimensional images were obtained in multiple planes using
standard transducer positions. Continuous wave Doppler ex-
aminations from the apical window were performed and
guided by color flow mapping two-dimensional echocardiogra-
phy to estimate the maximal LVOT gradient. Care was taken
to separate the mitral regurgitation signal from that of the
LVOT gradient. The LVOT gradient was estimated using a
modified Bernoulli equation. After pacemaker implantation,
Doppler evaluation was performed in blinded manner with
regard to changes in pacemaker rates, modes and AV intervals.
Holter monitoring. Twenty-four hour Holter monitoring
was performed to assess intrinsic atrial rate variability through-
out the day. QRS complexes were assessed for 100% ventric-
ular capture with maximal QRS duration. Holter monitoring
also allowed for analysis of any significant atrial or ventricular
arrhythmia.
Exercise treadmill testing. All patients $8 years age un-
derwent treadmill testing using the standard Bruce protocol.
Exercise duration, rest and maximal heart rates and blood
pressure (using manual blood pressure cuff), and any signifi-
cant symptoms were documented. The electrocardiogram
(ECG) was analyzed to determine whether appropriate atrial
tracking, 100% ventricular pacing and capture with maximal
pre-excitation were present after pacemaker implantation.
Atrial or ventricular arrhythmias, or both, were noted. Doppler
evaluation of maximal exercise LVOT estimated gradient was
not performed.
Cardiac catheterization. Patients received premedication
with oral midazolam or diazepam. During the first cardiac
catheterization, a combination of midazolam and fentanyl or
morphine intravenously was used for sedation and analgesia,
respectively. Xylocaine was infused for local analgesia. To
determine the effect of DCP, beta-adrenergic or calcium
channel blocking agent treatment, or both, was continued in
each patient up to the time of catheterization. Hemodynamic
data obtained during baseline normal sinus rhythm included
left ventricular systolic and end diastolic pressures, aortic
pressure, pulmonary artery pressure, pulmonary wedge pres-
sure and thermodilution cardiac output using the Swan-Ganz
catheter. Left ventricular pressure was recorded through a
retrograde arterial approach, taking care to position the cath-
eter apically and using a pigtail catheter to avoid catheter
entrapment with resultant falsely elevated apical pressures.
Two 5F quadrapolar electrophysiologic catheters were posi-
tioned for pacing at the right ventricular apex close to the
interventricular septum and in the right atrial appendage.
Temporary DCP with an external Intermedics Relay pace-
maker (model 294-03) was performed. Hemodynamic data
were remeasured during P-synchronous ventricular pacing and
AV sequential pacing at rates of 100 to 120 beats/min with AV
intervals of 75 to 125 ms. The shortest AV interval producing
right ventricular pre-excitation on the surface ECG with the
least LVOT gradient was determined. Pacing was performed
10 min for stabilization before repeat measurement of hemo-
dynamic measures during each mode, rate or AV interval
variable change. There were no complications during this
temporary pacing procedure.
The second catheterization was scheduled at least 18
months after pacemaker implantation. Patients received pre-
medication with oral midazolam or diazepam, and intravenous
midazolam or fentanyl or morphine was given for sedation and
analgesia. Complete hemodynamic evaluation was performed
as previously described at the patient’s current pacemaker
mode and timing interval settings. Long-term beta- or calcium
channel blocker treatment, or both, was continued up to the
time of study.
Pacemaker implantation. Seven patients (Patients 1 to 7)
underwent implantation of an Intermedics Cosmos II pulse
generator (model 284-05). This pulse generator was chosen in
view of its capabilities for acquiring and storing diagnostic
Abbreviations and Acronyms
AV 5 atrioventricular
DCP 5 dual-chamber pacing
ECG 5 electrocardiogram
HOCM 5 hypertrophic obstructive cardiomyopathy
LVOT 5 left ventricular outflow tract
735JACC Vol. 29, No. 4 RISHI ET AL.
March 15, 1997:734–40 PACING FOR PEDIATRIC HOCM
data, DCP capabilities and highly variable AV interval settings.
Six patients had transvenous leads, and one patient (4 years
old, Patient 5) underwent implantation of an epicardial system
because of her small size; bipolar leads were placed in/on the
right atrial appendage and at the right ventricle apex close to
the interventricular septum. A special Intermedics program-
ming module allowed a decrease in the AV interval to a
minimum of 30 ms.
Pacemaker analysis. Pacemaker analysis included assess-
ment of intrinsic rhythm and atrial and ventricular sensing and
pacing thresholds. Pacemaker diagnostic data were reviewed
for the percentage of the time that the patient was actually
paced. Careful adjustments of the AV interval and pacing rates
were performed simultaneously with Doppler echocardiogra-
phy to achieve the least LVOT gradient without mitral inflow
obstruction.
Statistics. Serial catheterization measurements were statis-
tically analyzed using the Student t test for paired data. The
Wilcoxon signed-rank test was used for analysis of question-
naire data comparing patient scores before and after pace-
maker implantation. Analysis of variance for repeated mea-
sures (Bonferroni method) was used to evaluate repeated
Doppler estimates of LVOT gradients. A p value #0.05 was
considered significant. Data are presented as mean value 6
SD. Confidence intervals for proportions were calculated using
the mid-p exact method (22).
Results
Demographics. Table 1 summarizes age, gender and med-
ications for Patients 1 to 10 (four female, six male; mean age
11.1 6 6 years, range 1 to 17.5). Each patient had been
previously unsuccessfully treated with either beta-blockers
(four patients) or calcium channel blockers (two patients), or
both (four patients). The diagnosis of HOCM was made by
echocardiography, which demonstrated severe hypertrophy of
the myocardium (septum or left ventricular free wall) in the
absence of an identified etiology. Each patient (except for
Patient 2), was receiving concomitant drug therapy at the time
of the temporary pacing evaluation. After pacemaker implan-
tation, drug therapy was used in Patients 2 and 6 for treatment
of asymptomatic nonsustained ventricular tachycardia and for
slowing of AV node conduction in Patients 1, 3 to 5 and 7.
Baseline cardiac catheterization with temporary DCP.
Seven of 10 patients (70%, 95% confidence interval 38.0% to
91.7%; mean age 13 6 5 years, range 4 to 17.5) showed
hemodynamic improvement during temporary DCP at first
cardiac catheterization. Catheterization data (from first and
second catheterizations) for these seven patients are reported
in Table 2. Compared with baseline sinus rhythm (Table 3),
temporary DCP at AV intervals 75 to 125 ms resulted in
Table 1. Patient Demographics
Pt No./
Gender Previous Rx
Cath 1 Cath 2
Age Rx Age Rx
1/F V 17 yr, 5 mo BB 19 yr, 10 mo BB
2/M BB,V 15 yr, 8 mo 0 17 yr, 8 mo BB
3/M BB,V 13 yr, 1 mo BB 15 yr, 1 mo V
4/M BB,V 8 yr, 5 mo BB 10 yr, 4 mo BB
5/F BB 4 yr, 2 mo BB 5 yr, 10 mo BB
6/M BB 17 yr, 6 mo BB 19 yr BB
7/M BB 14 yr, 6 mo BB — —
8/F BB 1 yr BB — —
9/F V 5 yr V — —
10/M BB,V 14 yr, 1 mo BB — —
BB 5 beta-adrenergic blocking agent; Cath 5 catheterization; F 5 female;
M 5 male; Pt 5 patient; Rx 5 medical treatment; V 5 verapamil; — 5 not
applicable.













BL TP PP BL TP PP BL TP PP BL TP PP BL TP PP
1 175 110 130 100 100 104 75 10 26 3.0 — 3.5 19 10 14
2 134 110 105 90 105 108 44 5 0 2.8 3.3 3.6 18 11 11
3 140 118 119 100 108 85 40 10 34 3.7 3.4 2.6 20 12 19
4 140 90 94 82 84 80 58 6 14 4.1 — 2.9 14 11 10
5 140 118 95 85 114 80 55 4 15 5.1 4.6 3.8 16 14 15
6 163 130 103 120 120 93 43 10 10 3.8 3.8 2.9 18 17 7
7 160 120 — 100 105 — 60 15 — 2.0 2.5 — 14 14 —
Ao 5 aortic; BL 5 baseline hemodynamic data; CI 5 cardiac index; LV 5 left ventricular; LVOT 5 left ventricular outflow tract; PCW 5 pulmonary capillary
wedge; PP 5 hemodynamic data during permanent pacing at second catheterization; Pt 5 patient; TP 5 hemodynamic data during temporary pacing at first
catheterization; — 5 not applicable.








LV systolic pressure (mm Hg) 1506 15 114 6 13 , 0.001
Ao systolic pressure (mm Hg) 976 13 105 6 11 NS
LVOT gradient (mm Hg) 54 6 12 9 6 4 , 0.001
CI (liter/min per m2) 3.5 6 1.0 3.5 6 0.8 NS
PCW pressure (mm Hg) 17 6 2 13 6 2 0.005
Abbreviations as in Table 2.
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significantly lower (p , 0.05) left ventricular systolic pressure
(150 6 15 vs. 114 6 13 mm Hg), LVOT gradient (54 6 12 vs.
9 6 4 mm Hg) and pulmonary capillary wedge pressure (17 6
2 vs. 13 6 2 mm Hg). No change was noted in cardiac index
(3.5 6 1.0 vs. 3.5 6 0.8 liter/min per m2) or aortic systolic
pressure (97 6 13 vs. 105 6 11 mm Hg).
Patients 8 and 9 were never satisfactorily or consistently
paced during temporary DCP. Both patients had fast sinus
atrial rates and rapid AV conduction, despite sedation, and a
reliable ventricular-paced pre-excited QRS complex was never
achieved. The effects of temporary pacing therefore could not
be adequately assessed.
Previous medical trials with both calcium channel and
beta-blockers had failed in Patient 10; temporary DCP did not
reduce the LVOT gradient. After catheterization, further
review of his echocardiographic evaluation indicated a congen-
ital mitral valve abnormality (Fig. 1), defined as upward
displacement of the hypertrophied mitral valve papillary mus-
cles into the LVOT gradient, with direct anomalous insertion
of the mitral valve papillary muscles into the valve leaflets,
without intervening chordae tendinae (23). This patient was
referred for mitral valve replacement, which eliminated the
LVOT gradient.
Left ventricular outflow tract gradient Doppler evaluation.
Table 4 summarizes LVOT gradient Doppler evaluation for
Patients 1 to 7. Preimplantation Doppler estimates of LVOT
obstruction form the basis for serial comparison to subsequent
outpatient Doppler evaluations during pacemaker reprogram-
ming. Doppler evaluations are reported for 1-week and 1-, 3-,
6-, 12- and 18-month intervals after implantation. For Patient
4, Doppler evaluation predicted a LVOT gradient 17% above
the baseline value at his 1-week evaluation; review of the ECG
showed that his programmed AV interval was too long to
achieve a widely pre-excited QRS complex. After reprogram-
ming of his AV interval, he subsequently demonstrated a
decrease in his Doppler predicted LVOT gradient.
At 1-week Doppler gradients had decreased significantly
(p , 0.05) compared with baseline data. Subsequent Doppler
evaluation of the LVOT predicted gradient showed no appre-
ciable change over the remaining 17 months of our evaluation.
Exercise treadmill testing. Patients 1 to 4 and 6 and 7
underwent serial treadmill testing. Maximal heart rate re-
sponse before pacemaker implantation was 167 6 14 versus
170 6 13 beats/min after pacemaker implantation, not signif-
icantly different. Total exercise time (Table 5) before implan-
tation was 8.0 6 1.8 versus 9.9 6 1.8 min after implantation
(p , 0.05). No patient had exercise-induced ventricular or
supraventricular tachycardia. Several patients showed an occa-
sional decrease in the width of their ventricular-paced QRS
complex at upper exercise heart rates, due to competition with
enhanced AV conduction at maximal exercise. Doppler inter-
rogation of the LVOT at maximal exercise was not performed.
Pacemaker diagnostic data and Holter monitoring. When
optimally programmed (AV intervals 60 to 110 ms), no patient
showed ,98% ventricular paced complexes with either AV
sequential or P-synchronous ventricular pacing. Holter moni-
toring was used in conjunction to verify that the paced QRS
complexes were widely pre-excited secondary to control of
ventricular activation by the pacemaker.
Figure 1. Pathologic mitral valve and papillary muscle specimen from
Patient 10. Direct papillary muscular insertion into the mitral valve
leaflets can be seen.




Left Ventricular Outflow Tract Gradient (mm Hg)
BL 1 wk 1 mo 3 mo 6 mo 12 mo 18 mo
1 64 8 20 8 8 6 12
2 55 15 14 13 16 15 15
3 40 15 11 13 13 10 14
4 77 90 43 35 12.5 36 15
5 50 16 15 16 25 10 25
6 51 13 9 10 — 11 10
7 72 20 24 28 36 36 —
Mean 58.0 25.0* 19.4* 17.6* 18.4* 17.7* 15.2*
SD 13.0 28.8 11.6 10.0 10.3 12.8 5.2
*p , 0.05 versus baseline Doppler evaluation before implantation. Abbre-
viations as in Table 2.















*Patient (Pt) 5 did not undergo permanent treadmill evaluation because of
young age. NA 5 not applicable.
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Radiofrequency ablation. Patient 5 underwent AV node
radiofrequency ablation without complication, after outpatient
ECG evaluation repeatedly revealed inadequate ventricular
paced pre-excitation associated with worsening symptoms.
Shortening of the programmed AV interval to 30 to 50 ms had
acutely resulted in pulmonary edema immediately after pace-
maker implantation, but at longer programmed AV intervals,
rapid intrinsic AV node conduction prevented rapid maximal
pacing benefits.
Questionnaire data. Six patients and their parents com-
pleted serial questionnaires; Patient 7 declined the follow-up
questionnaire. Before and subsequent to pacemaker implanta-
tion, no patient complained of presyncope, and no patient had
experienced syncope or sudden death episodes. After implan-
tation, each patient was judged by himself/herself and parents
as symptomatically “improved.” Chest pain and palpitations
were uncommon complaints before pacemaker implantation
and were not significantly improved subjectively by pacemaker
implantation. In contrast, significant (p , 0.05) improvement
was seen in both dyspnea on exertion (3.5 vs. 0.5, median
score) and exercise intolerance (3.5 vs. 0.5, median score).
Patients 1 to 3 each improved symptomatically enough to
participate in neighborhood aerobic, low intensity sports (ten-
nis, softball). Patient 5 showed a dramatic decrease in pulmo-
nary symptoms (frequently requiring hospital admission) at-
tributed to pulmonary venous congestion.
Follow-up catheterization. The second catheterization was
performed 23 6 4 months after pacing system implantation in
six of seven patients (Patient 7 declined reevaluation). Age at
reevaluation was 14.6 6 5.5 years. Each patient was paced in
the DDD mode, with pacing rates from 80 to 120 beats/min
AV intervals programmed from 75 to 110 ms. Results were
similar to the temporary pacing hemodynamic findings noted
earlier in this group of six study patients (Table 6). Sustained
significant (p , 0.05) decreases (compared with preimplanta-
tion values) in left ventricular systolic pressure (149 6 16 vs.
1086 14 mmHg), left ventricular outflow gradient (536 13 vs.
16 6 11 mm Hg) and pulmonary capillary wedge pressure
(18 6 2 vs. 12 6 4 mm Hg) were measured. Aortic systolic
pressure (966 14 vs. 926 12 mmHg) and cardiac index (3.86
0.8 vs. 3.2 6 0.5 liters/min per m2 were unchanged. No
statistical differences were noted in any of the five measured
hemodynamic indexes between temporary pacing evaluation
and the subsequent follow-up pacing catheterization.
Discussion
Main findings. The present study demonstrates that per-
manent DCP can decrease symptoms, increase exercise time
and improve hemodynamic variables in children with HOCM
who show therapeutic response to temporary DCP. Temporary
DCP in 7 (70%) of 10 patients (95% confidence interval 38.0%
to 91.7%) significantly decreased left ventricular pressure,
LVOT gradient and pulmonary capillary wedge pressure; this
acute change was sustained, both as assessed by noninvasive
Doppler evaluation during pacing analysis and at follow-up
cardiac catheterization 23 months later. The reduction in
LVOT gradient is consistent with hemodynamic data from
adult studies (17–20,24).
Importantly, each of these seven patients had been symp-
tomatic with LVOTDoppler gradients.40 mmHg despite the
use of medications before pacemaker implantation. Individu-
ally, each patient reported symptomatic improvement, con-
firmed by parents. Exercise treadmill time was increased
significantly for the group, and each patient tested serially,
except Patient 7, showed an increase in total treadmill exercise
duration. Serial questionnaires were administered to patients
and their parents to more accurately define symptomatic
change, fully realizing the difficulty quantifying symptoms in
young children and possible placebo effect of DCP. Other
investigators have noticed subjective symptomatic improve-
ment with DCP, despite only modest (though significant)
increases in exercise times (19,20). No studies have reported
the evaluation of exercise-related gradients after pacemaker
implantation; it is possible that pacing may improve symptoms
during exercise by relieving exercise-induced LVOT obstruc-
tion.
Effects of pacing on diastolic function. Debate still contin-
ues about the impact of DCP on diastolic function in patients
with HOCM. Diastolic dysfunction contributes greatly to the
symptoms in the majority of patients with HOCM. Diastolic
filling of the left ventricle is a complex sequence of many
interrelated events, each of which is difficult to accurately
measure in the beating heart. Duch et al (21) and McDonald
and Mauer (20) have shown a beneficial effect of pacing on
diastolic function, consistent with our data showing a de-
creased pulmonary capillary wedge pressure reflecting a de-
crease in left ventricular end-diastolic pressure. The exact
physiologic mechanism causing the decrease in pulmonary









LV systolic pressure (mm Hg) 1496 16 113 6 13 108 6 14 0.002 , 0.001 NS
Ao systolic pressure (mm Hg) 966 14 105 6 13 92 6 12 NS NS NS
LVOT gradient (mm Hg) 53 6 13 8 6 3 16 6 11 , 0.001 , 0.001 NS
CI (liter/min per m2) 3.8 6 0.8 3.8 6 0.6 3.2 6 0.5 NS NS NS
PCW pressure (mm Hg) 18 6 2 13 6 3 12 6 4 0.004 0.03 NS
Abbreviations as in Table 2.
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capillary wedge pressure with pacing is incompletely under-
stood. In contrast, Bettocci et al. (25) reported impaired
diastolic function during AV pacing, as evidenced by increased
pulmonary capillary wedge pressure during AV pacing in 16
patients with hypertrophic cardiomyopathy. These investiga-
tors demonstrated that although AV pacing did relieve LVOT
obstruction in patients with HOCM, diastolic function was
impaired, as shown by the prolongation of the time constant of
isovolumetric relaxation despite the decrease in left ventricular
systolic pressure and a decrease in peak filling rate despite the
elevation of pulmonary capillary wedge pressure. The acute
Doppler echocardiographic and catheterization hemodynamic
study by Nishimura et al. (24) reported deterioration of
diastolic function variables during pacing, greater at short AV
intervals than at long AV intervals. The shortest AV interval
evaluated (60 ms) in their adult patients was shorter than the
optimal AV interval in our pediatric patients; in these patients
left atrial pressure was increased, presumably due to atrial
contraction against a closed mitral valve. They also reported a
significant, though modest, decrease in LVOT gradient from
73 6 45 to 61 6 41 mm Hg (p , 0.05) during DCP at optimal
AV delay.
Importance of paced AV interval. Benefits to patients with
HOCM accrue from permanent DCP presumably because of a
change in septal activation by the right ventricular pacing
(17,18,20), although still maintaining AV synchrony. Many
studies, including Nishimura et al. (24), have emphasized the
critical impact that the appropriate AV interval has on the
success of this treatment modality. Patients may often require,
even after the institution of pacing, concomitant drug therapy
or AV node ablation, or both, to achieve optimal pacing
conditions. Determination of the optimal AV delay may prove
to be especially time-consuming and difficult in pediatric
patients with more rapid intrinsic AV conduction. Selection of
a newer generation of implanted pacemaker with rate-adaptive
AV intervals may allow for custom tuning of AV intervals to
provide widely pre-excited paced QRS complexes both at rest
and during exercise.
Ventricular remodeling. Reduction or elimination of
chronic LVOT obstruction by DCP theoretically could cause
regression of left ventricular and septal hypertrophy second-
ary to the outflow obstruction itself, without affecting the
primary cardiomyopathic process itself. This remodeling has
been espoused by Fananapazir et al. (19). Due to the varied
morphologic presentation of HOCM with asymmetric hy-
pertrophy (26,27), great care must be exercised to reproduce
exactly the M-mode plane used to measure serial interven-
tricular septal and left ventricular freewall dimensions.
Echocardiographically derived left ventricular mass, depen-
dent on symmetry of the ventricular dimensions, is not
applicable in this disease process (28). In the future, three-
dimensional left ventricular mass estimations (29) may offer
the most reliable and accurate measure for patients with
HOCM.
Other HOCM treatment options. Surgical myectomy or
mitral valve replacement, or both, successfully relieves
symptoms as well as decreases LVOT gradient (8,9,10,
11,13–15). Although operative mortality approximates 1%,
surgical procedures have not yet been shown to alter the
natural history of this disease process. A recent preliminary
report (30) describes experience with nonsurgical myocar-
dial reduction by selective catheterization of the first major
septal artery followed by alcohol infusion to produce a
localized infarct. For patients unresponsive to medications,
or troublesome drug side effects, cardiac DCP may repre-
sent a reasonable option before an open cardiovascular
surgical procedure.
Pediatric pacing. Permanent DCP is now the standard of
care for many rhythm disturbances in children; pacing in
HOCM is a novel application of this widely used therapy.
Important developments in pacing technology include im-
proved lead systems, smaller energy sources and multipro-
grammable pulse generators (31). Pulse generators considered
for the patient group should have rate-responsive features,
variable AV delays with short AV interval options (#50 ms)
and diagnostic counters.
Cautions for pediatric HOCM pacing. A recent editorial
(32) sounded a cautionary note regarding DCP as a treat-
ment strategy for patients with HOCM. Clearly, the ultimate
role of DCP for patients with HOCM has yet to be
completely defined. Certain considerations for pacing in
pediatric patients may prove to be especially important.
Smaller pediatric patients may still require epicardial pace-
maker systems through either a sternotomy or thoracotomy.
These smaller patients tend to have faster heart rates and
shorter AV conduction intervals, which may make program-
ming pacemaker variables more difficult. Congenital abnor-
malities of the mitral valve (23), although rare, can cause
fixed intracavitary obstruction and prove to be unresponsive
to pacing. Echocardiographic diagnosis of these mitral valve
abnormalities before even temporary pacing should help
direct these patients to more appropriate surgical mitral
valve replacement.
Summary. For our study cohort, permanent DCP de-
creased LVOT gradient in selected (those responding to
temporary DCP) pediatric patients with HOCM. This report
represents our first evaluation of permanent pacing in pediat-
ric patients with HOCM; our cohort was a limited patient
series. A trial of temporary and ultimately permanent pacing
may be worth considering as a treatment option in pediatric
patients with HOCM who are unresponsive to medications.
Symptoms unresponsive to long-term medications may like-
wise be dramatically improved in certain patients. Technical
limitations still exist for application of this pacing technique in
younger pediatric patients with HOCM. Ultimately the role of
DCP for pediatric patients with HOCM may best be defined
through collaborative, multicentered trials.
We thank Andrea Fish for expertise with manuscript preparation and statistical
analysis.
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